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Patients: With advanced non–small-cell lung cancer (NSCLC) har-
boring, the anaplastic lymphoma kinase (ALK) gene rearrangement 
often responds impressively to ALK inhibitors, such as crizotinib. 
Acquired tumor resistance to ALK inhibition develops after a median 
progression-free survival of 7.7 to 10.9 months, with several mecha-
nisms of resistance already described. Second generation ALK inhib-
itors, such as ceritinib, may overcome some of these mechanisms and 
have known efficacy in brain metastases. Their effect on intramedul-
lary spinal cord metastases, a rare form of central nervous system 
metastases, is unknown.
A 42-year-old man complained of cough and weight loss (4 kg) over 6 months. He had no occupational expo-
sure or family history of cancer and was a light smoker 
(<5 pack-years). Computerized tomography (CT) revealed 
a left upper lobe tumor with pleural thickening, subse-
quent biopsy of which led to a diagnosis of T1N2M1a lung 
adenocarcinoma. Mutational status was not assessable at 
this time because of inadequate tissue quantity. Between 
January and May 2012, he was treated with initial plati-
num-pemetrexed chemotherapy and second line erlotinib. 
Two further biopsies were performed at the point of dis-
ease progression during both treatments: the first revealed 
ALK expression by immunohistochemistry, but no ALK 
rearrangement by FISH because of technical issues. The 
second confirmed ALK rearrangement by FISH, and 
crizotinib was, therefore, introduced in June 2012. A par-
tial response to crizotinib was evident for 7 months, at 
which point asymptomatic brain metastases were noted 
on cranial imaging by magnetic resonance image (MRI) 
in February 2013. Crizotinib was stopped, and the patient 
underwent whole brain radiotherapy, with crizotinib 
resumed thereafter.
In July 2013, the patient experienced motor weak-
ness of the right leg (grade 3 of 5), difficulty with walking 
and hypoesthesia of the chest: MRI of whole spine showed 
intramedullary metastases at C6, T1-2, and T4 levels. 
Palliative spinal irradiation was performed (30 Gy in 10 
fractions, directed at C4-T5). Six weeks after radiotherapy 
completion, MRI of spine showed no improvement of spi-
nal metastases, and the patient remained symptomatic. In 
October 2013, because no further clinical or radiological 
benefit was evident, crizotinib was discontinued and ceri-
tinib was started at 750 mg/d within an expanded access 
program. The patient’s motor weakness quickly improved 
(grade 4 of 5), allowing him to mobilize more freely for 
the first time in months. After two months, aspartate trans-
aminase and alanine aminotransferase levels exceeded 
seven times the upper limit of normal, and ceritinib was 
consequently withdrawn for 1 week then reinstated at 
600 mg/d with no further problems in liver function tests. 
Interval MRI of whole spine after 2 months of ceritinib 
treatment showed a reduction in size of the T1–T2 lesion 
(Fig. 1). Thirteen months after initiation of ceritinib, the 
patient remains in stable clinical condition, and there is 
still no evidence of any new systemic or central nervous 
system lesion.
Discussion
CNS relapse during crizotinib treatment is well charac-
terized in ALK+ NSCLC patients.1 Intramedullary spi-
nal cord metastases (ISCMs) are rare, occurring in less 
than 1% of all cancer patients.2 Incidence and outcome 
of ISCMs have been poorly described in ALK+ NSCLC 
patients. Gainor et al.3 reported three patients with ALK-
positive NSCLC featuring ISCMs and prior crizotinib. As 
with our patient, these patients all had a history of brain 
metastases and underwent spinal irradiation, but none of 
them were exposed to a second generation inhibitor, such 
as ceritinib.
We previously described a case of leptomeningeal 
carcinomatosis (LC), another form of CNS metastases, in a 
women receiving ceritinib who had experienced CNS progres-
sion on crizotinib.4 As with our patient, this patient required a 
dose reduction to 600 mg/d, because of grade 2 nausea. More 
recently, Gainor et al.5 reported four patients with leptomen-
ingeal carcinomatosis successfully treated with the second 
generation ALK inhibitor, alectinib, after failure of both crizo-
tinib and ceritinib.
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Despite harboring crizotinib resistant ISCMs, our 
patient continues to respond impressively to ceritinib. Here, 
we cannot completely exclude a delayed effect of radio-
therapy, or indeed an enhancement of radiotherapy effect by 
ceritinib, although this seems potentially unlikely given the 
clinical timelines involved.
REFEREncEs
 1. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in 
advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385–2394.
 2. Sung WS, Sung MJ, Chan JH, et al. Intramedullary spinal cord metas-
tases: a 20-year institutional experience with a comprehensive literature 
review. World Neurosurg 2013;79:576–584.
 3. Gainor JF, Ou SH, Logan J, Borges LF, Shaw AT. The central nervous 
system as a sanctuary site in ALK-positive non-small-cell lung cancer. 
J Thorac Oncol 2013;8:1570–1573.
 4. Arrondeau J, Ammari S, Besse B, Soria JC. LDK378 compassionate use 
for treating carcinomatous meningitis in an ALK translocated non-small-
cell lung cancer. J Thorac Oncol 2014;9:e62–e63.
 5. Gainor JF, Sherman CA, Willoughby K, et al. Alectinib salvages CNS 
metastases in ALK-positive lung cancer patients previously treated with 
crizotinib and ceritinib. J Thorac Oncol 2015;10:232–236.
FiGuRE 1.  Magnetic resonance imaging of 
T1-enhanced sequence in sagittal axis (A) before 
and (B) after 2 months of LDK378 (arrows).
